Carbon Ion Radiotherapy Acts as the Optimal Treatment Strategy for Unresectable Liver Cancer During the Coronavirus Disease 2019 Crisis.
Carbon Ion Radiotherapy Acts as the Optimal Treatment Strategy for Unresectable Liver Cancer During the Coronavirus Disease 2019 Crisis.
复制标题
DOI：
10.3389/fpubh.2021.767617
复制
发表时间：
2021
影响因子：
5.2
通讯作者：
Liu R
中科院分区：
文献类型：
--
作者：
Li Z;Li Q;Wang X;Li S;Chen W;Jin X;Liu X;Dai Z;Liu X;Zheng X;Li P;Zhang H;Zhang Q;Luo H;Liu R
2019冠状病毒病（COVID-19）大流行极大地扰乱了肝癌患者的正常治疗，并增加了他们的死亡风险。治疗安全性的权重被显著放大，以便决策最大限度地减少严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的风险。在此，对碳离子放射治疗（CIRT）治疗不能切除的肝癌（ULC）的安全性和有效性进行评价，并分享中国经验，以解决SARS-CoV-2引起的ULC治疗困境。由于COVID-19大流行，世界已成为一个社区，因此收集了全球研究以评估CIRT治疗ULC的效果。我们不仅检索了5个国际数据库，包括科克伦图书馆、Web of Science、PubMed、Embase和Scopus，还对其他来源进行了补充检索。根据CIRT在中国的进展和CIRT治疗ULC的前瞻性临床试验，介绍了中国抗击COVID-19的经验。共有19项研究，涉及813例ULC患者被纳入系统评价。定性综合评价显示，与经动脉化疗栓塞（TACE）相比，CIRT可获得上级的总生存率、局部控制和相对的肝脏保护。系统结果表明，无创CIRT可以显着减少对ULC患者的伤害，同时获得上级抗癌效果。根据中国的经验，CIRT让院内远程医疗（TMIH）在ULC的整个治疗过程中保持足够的人与人的物理距离，这对于切断SARS-CoV-2的传播途径具有重要意义。此外，CIRT可以最大限度地提高住院和门诊服务（UHO）的利用率。总的来说，CIRT治疗ULC患者不仅允许TMIH和最大化UHO，而且具有安全性和有效性的兼容优势。因此，CIRT应被确定为治疗适当ULC的最佳策略，当我们需要最大限度地降低SARS-CoV-2感染的风险，并在前所未有的COVID-19危机的背景下提高医疗服务能力时。
The coronavirus disease 2019 (COVID-19) pandemic has greatly disrupted the normal treatment of patients with liver cancer and increased their risk of death. The weight of therapeutic safety was significantly amplified for decision-making to minimize the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Herein, the safety and effectiveness of carbon ion radiotherapy (CIRT) for unresectable liver cancer (ULC) were evaluated, and Chinese experiences were shared to solve the predicament of ULC treatment caused by SARS-CoV-2. Worldwide studies were collected to evaluate CIRT for ULC as the world has become a community due to the COVID-19 pandemic. We not only searched five international databases including the Cochrane Library, Web of Science, PubMed, Embase, and Scopus but also performed supplementary retrieval with other sources. Chinese experiences of fighting against COVID-19 were introduced based on the advancements of CIRT in China and a prospective clinical trial of CIRT for treating ULC. A total of 19 studies involving 813 patients with ULC were included in the systematic review. The qualitative synthetic evaluation showed that compared with transarterial chemoembolization (TACE), CIRT could achieve superior overall survival, local control, and relative hepatic protection. The systematic results indicated that non-invasive CIRT could significantly minimize harms to patients with ULC and concurrently obtain superior anti-cancer effectiveness. According to the Chinese experience, CIRT allows telemedicine within the hospital (TMIH) to keep a sufficient person-to-person physical distance in the whole process of treatment for ULC, which is significant for cutting off the transmission route of SARS-CoV-2. Additionally, CIRT could maximize the utilization rate of hospitalization and outpatient care (UHO). Collectively, CIRT for ULC patients not only allows TMIH and the maximized UHO but also has the compatible advantages of safety and effectiveness. Therefore, CIRT should be identified as the optimal strategy for treating appropriate ULC when we need to minimize the risk of SARS-CoV-2 infection and to improve the capacity of medical service in the context of the unprecedented COVID-19 crisis.
登录
查看更多内容
影响因子：
2.1
作者：
Harada, Mayumi;Karasawa, Kumiko;Nemoto, Kenji
通讯作者：
Nemoto, Kenji
影响因子：
5.7
作者：
Imada, Hiroshi;Kato, Hirotoshi;Tsujii, Hirohiko
通讯作者：
Tsujii, Hirohiko
影响因子：
28.2
作者：
Dai, Mengyuan;Liu, Dianbo;Cai, Hongbing
通讯作者：
Cai, Hongbing
临床相关碳离子束的纳剂量量和 RBE
影响因子：
3.8
作者：
Dai, Tianyuan;Li, Qiang;Zhang, Xiaofang
通讯作者：
Zhang, Xiaofang
DOI：
10.1016/j.ijrobp.2004.01.032
发表时间：
2004-08-01
影响因子：
7
作者：
Kato, H;Tsujii, H;Ohto, M
通讯作者：
Ohto, M